Author:
Feichtenschlager Valentin,Chen Linan,Zheng Yixuan James,Ho Wilson,Sanlorenzo Martina,Vujic Igor,Fewings Eleanor,Lee Albert,Chen Christopher,Callanan Ciara,Lin Kevin,Qu Tiange,Hohlova Dasha,Vujic Marin,Hwang Yeonjoo,Lai Kevin,Chen Stephanie,Nguyen Thuan,Muñoz Denise P,Kohwi Yoshinori,Posch Christian,Daud Adil,Rappersberger Klemens,Kohwi-Shigematsu Terumi,Coppé Jean-Philippe,Ortiz-Urda Susana
Abstract
AbstractFinding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using a discovery approach combining experimental models and unbiased computational analysis complemented by validation in patient biospecimens, we identified a nuclear-enriched lncRNA (AC004540.4) that is upregulated in NRAS/MAPK-dependent melanoma, and that we named T-RECS. Considering potential innovative treatment strategies, we designed antisense oligonucleotides (ASOs) to target T-RECS. T-RECS ASOs reduced the growth of melanoma cells and induced apoptotic cell death, while having minimal impact on normal primary melanocytes. Mechanistically, treatment with T-RECS ASOs downregulated the activity of pro-survival kinases and reduced the protein stability of hnRNPA2/B1, a pro-oncogenic regulator of MAPK signaling. Using patient- and cell line- derived tumor xenograft mouse models, we demonstrated that systemic treatment with T-RECS ASOs significantly suppressed the growth of melanoma tumors, with no noticeable toxicity. ASO-mediated T-RECS inhibition represents a promising RNA-targeting approach to improve the outcome of MAPK pathway-activated melanoma.
Funder
Verein zur Förderung der Dermatologischen Forschung
Impact Melanoma
Outrun the Sun, Inc. 2019 National Melanoma Research Scholar Award
HDFCCC Laboratory for Cell Analysis Shared Resource Facility
Publisher
Springer Science and Business Media LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献